Generic Name and Formulations:
Infliximab 100mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.
Company:
Janssen Biotech, Inc.
To reduce signs/symptoms, inhibit progression of structural damage, and improve physical function in psoriatic arthritis and with methotrexate in moderately to severely active rheumatoid arthritis (RA). To reduce signs/symptoms of active ankylosing spondylitis.
Give by IV infusion over at least 2 hours. RA: 3mg/kg at weeks 0, 2, 6, then every 8 weeks. May increase to 10mg/kg or give every 4 weeks. Ankylosing spondylitis: 5mg/kg at weeks 0, 2, 6, then every 6 weeks. Psoriatic arthritis: 5mg/kg at weeks 0, 2, 6, then every 8 weeks. All: max 5mg/kg in heart failure.
Not recommended.
Tumor necrosis factor-α blocker.
Moderate to severe heart failure (doses >5mg/kg). Allergy to murine proteins.
Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, viral, invasive fungal [treat empirically if develops], or other pathogens). Active infections: do not initiate therapy. Chronic or history of recurring infections or hematological abnormalities. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test/treat latent TB and HBV infection prior to initiating therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of HBV, or blood dyscrasias occurs; discontinue if serious or opportunistic infection, sepsis, HBV reactivation, or hematological abnormality develops. Discontinue if lupus-like syndrome with autoantibody formation, severe hypersensitivity reactions, or jaundice with liver enzymes ≥5xULN occurs. Pre-existing heart failure; closely monitor and discontinue if new or worsening symptoms occur. CNS demyelinating or seizure disorders; discontinue if significant CNS effects occur. Malignancies. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concurrent anakinra, abatacept, tocilizumab, live vaccines, or other TNF blockers: not recommended. Concomitant immunosuppressants (eg, corticosteroids, methotrexate) may increase risk of infection. May be potentiated by methotrexate. Concomitant CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine, theophylline): monitor and may need to adjust dose of these drugs. Caution with switching between DMARDs; overlapping may further increase the risk of infection.
Infection, infusion reactions (esp. after a period of no treatment), headache, abdominal pain, GI upset, fatigue, cough, fever, pain, dizziness, rash, pruritus, CHF, autoantibody formation; rare: malignancies (eg, lymphoma; esp children), optic neuritis, seizures, lupus-like syndrome, blood dyscrasias, hepatotoxicity.
Single-use vials—1
In moderately-to-severely active Crohn's disease: to reduce signs/symptoms and to induce and maintain clinical remission in adult and pediatric patients with inadequate response to conventional therapy. In fistulizing Crohn's disease: to reduce number of draining enterocutaneous and rectovaginal fistula(s); and maintain fistula closure in adults. In moderately-to-severely active ulcerative colitis (UC): to reduce signs/symptoms, to induce and maintain clinical remission and mucosal healing, and to eliminate corticosteroid use in adults with inadequate response to conventional therapy. In moderately-to-severely active UC: to reduce signs/symptoms and to induce and maintain clinical remission in pediatric patients with inadequate response to conventional therapy.
Give by IV infusion over at least 2 hours. Crohn's disease: 5mg/kg at weeks 0, 2, 6, then once every 8 weeks; if relapse, may increase to 10mg/kg; discontinue if no response by week 14. UC: 5mg/kg at weeks 0, 2, 6, then once every 8 weeks. Both: max 5mg/kg in heart failure.
<6yrs: not recommended. ≥6yrs: Give by IV infusion over at least 2 hours. Active Crohn's disease or UC: 5mg/kg at weeks 0, 2, 6, then once every 8 weeks.
Tumor necrosis factor-α blocker.
Moderate to severe heart failure (doses >5mg/kg). Allergy to murine proteins.
Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, viral, invasive fungal [treat empirically if develops], or other pathogens). Active infections: do not initiate therapy. Chronic or history of recurring infections or hematological abnormalities. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test/treat latent TB and HBV infection prior to initiating therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of HBV, or blood dyscrasias occurs; discontinue if serious or opportunistic infection, sepsis, HBV reactivation, or hematological abnormality develops. Discontinue if lupus-like syndrome with autoantibody formation, severe hypersensitivity reactions, or jaundice with liver enzymes ≥5xULN occurs. Pre-existing heart failure; closely monitor and discontinue if new or worsening symptoms occur. CNS demyelinating or seizure disorders; discontinue if significant CNS effects occur. Malignancies. Children: complete vaccinations before starting therapy (see literature). Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concurrent anakinra, abatacept, tocilizumab, live vaccines, or other TNF blockers: not recommended. Concomitant immunosuppressants (eg, corticosteroids, methotrexate) may increase risk of infection. May be potentiated by methotrexate. Concomitant CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine, theophylline): monitor and may need to adjust dose of these drugs. Caution with switching between DMARDs; overlapping may further increase the risk of infection.
Infections, infusion reactions (esp. after a period of no treatment), headache, abdominal pain, GI upset, fatigue, cough, fever, pain, dizziness, rash, pruritus, CHF, autoantibody formation; rare: malignancies (eg, lymphoma; esp children), optic neuritis, seizures, lupus-like syndrome, blood dyscrasias, hepatotoxicity.
Single-use vials—1
Severe chronic plaque psoriasis in adults who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
Give by IV infusion over at least 2 hours. 5mg/kg at weeks 0, 2, 6, then once every 8 weeks.
Not recommended.
Tumor necrosis factor-α blocker.
Moderate to severe heart failure (doses >5mg/kg). Allergy to murine proteins.
Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, viral, invasive fungal [treat empirically if develops], or other pathogens). Active infections: do not initiate therapy. Chronic or history of recurring infections or hematological abnormalities. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test/treat latent TB and HBV infection prior to initiating therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of HBV, or blood dyscrasias occurs; discontinue if serious or opportunistic infection, sepsis, HBV reactivation, or hematological abnormality develops. Discontinue if lupus-like syndrome with autoantibody formation, severe hypersensitivity reactions, or jaundice with liver enzymes ≥5xULN occurs. Pre-existing heart failure; closely monitor and discontinue if new or worsening symptoms occur. CNS demyelinating or seizure disorders; discontinue if significant CNS effects occur. Malignancies. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concurrent anakinra, abatacept, tocilizumab, live vaccines, or other TNF blockers: not recommended. Concomitant immunosuppressants (eg, corticosteroids, methotrexate) may increase risk of infection. May be potentiated by methotrexate. Concomitant CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine, theophylline): monitor and may need to adjust dose of these drugs. Caution with switching between DMARDs; overlapping may further increase the risk of infection.
Infections, infusion reactions (esp. after a period of no treatment), headache, abdominal pain, GI upset, fatigue, cough, fever, pain, dizziness, rash, pruritus, CHF, autoantibody formation; rare: malignancies (eg, lymphoma; esp children), optic neuritis, seizures, lupus-like syndrome, blood dyscrasias, hepatotoxicity.
Single-use vials—1